KM

Kenzie Maclsaac

Partner at Cure Ventures

Boston, Massachusetts

Overview 

Kenzie Maclsaac is a Partner at Cure Ventures in Boston, Massachusetts, with a Ph.D. from MIT and expertise in biomarker discovery, statistical computing, and machine learning. With a background that includes senior roles at Bristol Myers Squibb and Novartis, Maclsaac has a proven track record in translational bioinformatics and a strong focus on investing in early-stage companies in the healthcare and biotech sectors in Boston/New England.

Work Experience 

CV

Cure Ventures

  • Partner

    2022 - Current

BM

Bristol Myers Squibb

  • Senior Director

    2021 - 2022

  • Director, Translational Bioinformatics

    2018 - 2021

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.

bms.com
F

FogPharma

  • Director of Translational Bioinformatics

    2018 - 2018

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

Raised $530,271,035.00 from venBio Partners, RA Capital Management, Google Ventures, Marshall Wace, Samsara BioCapital, SymBiosis, Nextech Invest, Catalio Capital Management, Fidelity and T. Rowe Price.

fogpharma.com
NI

Novartis Institutes for BioMedical Research

  • Senior Investigator II - Bioinformatics

    2014 - 2018

M

Merck

  • Associate Principal Scientist

    2009 - 2014

    Genomics and target discovery for immunology and oncology drug discovery programs.

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.

Raised $5,586,000.00 from Private Capital Advisors.

merck.com
M

MIT

  • Research Affiliate

    2009 - 2010

Education 

Articles About Kenzie

Relevant Websites